Lowering Cholesterol:
Making the Right Choice

This section provides detailed scientific evidence for treatment recommendations, including major trial data and guideline development rationale.

Statin Evidence Base

Statins are the most extensively studied cardiovascular drugs in history. The Cholesterol Treatment Trialists' (CTT) Collaboration meta-analyses, incorporating individual patient data from over 170,000 participants across 27 randomized trials, established the foundation for modern statin guidelines.

Key findings from CTT meta-analyses:

• Each 1 mmol/L reduction in LDL-C reduces major vascular events by approximately 22%
• This benefit is consistent regardless of baseline LDL-C level—even those starting below 2.6 mmol/L benefit
• Benefit accrues over time: year 1 shows ~12% reduction, but years 2+ show the full ~22% per mmol/L
• The relationship is log-linear with no evidence of a threshold below which benefit stops

Absolute benefit depends on baseline risk: A 22% relative reduction means different things for different people. For someone with 2% 10-year risk, statins prevent ~4 events per 1,000 treated over 10 years. For someone with 30% risk, that same relative reduction prevents ~66 events per 1,000.

Statin Intolerance: The SAMSON Trial

The SAMSON (Self-Assessment Method for Statin Side-effects Or Nocebo) trial, published in NEJM 2020, used an elegant n-of-1 design to distinguish true pharmacological effects from nocebo phenomena.

60 patients who had previously stopped statins due to intolerable side effects entered a year-long protocol. Each month, they took either atorvastatin 20 mg, placebo, or nothing—in randomized order, blinded. They recorded daily symptom scores.

Results: On statin months, average symptom intensity was 8.0. On placebo months, it was 7.8. On no-tablet months, it was 6.7. The difference between statin and placebo was not statistically significant, but the difference between taking any tablet and taking nothing was. This proves that 90% of "statin side effects" are actually nocebo effects—caused by expectation of harm, not the drug itself.

After unblinding, 30 of 60 patients chose to restart statin therapy, suggesting that understanding the nocebo mechanism helped many overcome perceived intolerance.

PCSK9 Inhibitors: FOURIER and ODYSSEY OUTCOMES

PCSK9 inhibitors (evolocumab, alirocumab) represent a major advance in lipid-lowering therapy. These monoclonal antibodies prevent PCSK9 from degrading LDL receptors, dramatically increasing hepatic LDL clearance.

FOURIER (2017): 27,564 patients with established ASCVD on statin therapy were randomized to evolocumab or placebo. Evolocumab lowered LDL-C by 59% (from median 2.4 to 0.8 mmol/L). At median 2.2 years, cardiovascular events were reduced by 15% (HR 0.85). Importantly, ~500 patients achieved LDL-C <0.3 mmol/L with no excess adverse events.

ODYSSEY OUTCOMES (2018): 18,924 patients post-acute coronary syndrome randomized to alirocumab or placebo. Similar LDL reductions achieved. 15% reduction in major cardiovascular events. Notably, an exploratory analysis suggested mortality benefit (29% reduction) in the highest-risk tertile.

Cost-effectiveness: At initial list prices (~$14,000/year), PCSK9 inhibitors were not cost-effective for most patients. Price reductions (now ~$4,000-6,000/year) and restriction to high-risk patients have improved the value proposition.

Ezetimibe: IMPROVE-IT

Ezetimibe blocks intestinal cholesterol absorption via the NPC1L1 transporter. While it lowers LDL-C by only 15-20%, it does so through a mechanism independent of statins, making it an ideal add-on therapy.

The IMPROVE-IT trial (2015) randomized 18,144 post-ACS patients to simvastatin alone or simvastatin + ezetimibe. Adding ezetimibe lowered LDL-C from 1.8 to 1.4 mmol/L and reduced cardiovascular events by 6.4% over 7 years (NNT = 50). This was the first trial to demonstrate incremental benefit from LDL lowering below 1.8 mmol/L.

Bempedoic Acid: CLEAR Outcomes

Bempedoic acid inhibits ATP citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway. Crucially, it requires activation by an enzyme (ACSVL1) present in liver but not skeletal muscle—explaining why it doesn't cause myalgia.

The CLEAR Outcomes trial (2023) randomized 13,970 statin-intolerant patients to bempedoic acid or placebo. LDL-C was reduced by ~20% (from 3.6 to 2.8 mmol/L). Major cardiovascular events were reduced by 13% (HR 0.87). This was landmark evidence that lowering LDL-C prevents events even in patients who cannot tolerate statins.

The "Lower is Better" Evidence

Multiple lines of evidence support the principle that lower LDL-C concentrations produce greater cardiovascular benefit:

• CTT meta-regression shows a strictly linear relationship between LDL reduction and event reduction down to the lowest achieved levels
• FOURIER patients achieving LDL <0.5 mmol/L had the lowest event rates with no safety concerns
• GLAGOV imaging study showed linear relationship between achieved LDL and plaque regression, with no floor effect
• Mendelian randomization studies show lifelong low LDL (PCSK9 loss-of-function) produces 3x the benefit of late-life statin therapy

Current guidelines (ESC/EAS 2019) recommend LDL-C targets of <1.4 mmol/L for very high-risk patients, with consideration of even lower targets in recurrent events. There is no evidence of harm from very low LDL-C levels in adults.

Special Populations

Elderly (>75 years): Evidence for primary prevention in the elderly is less robust. STAREE trial is ongoing. For secondary prevention (existing disease), benefit clearly extends to the elderly. Shared decision-making is appropriate.

Women: Women have historically been underrepresented in lipid trials. Available data suggest similar relative benefit but lower absolute benefit (due to lower baseline risk). Guidelines recommend equal treatment thresholds.

Diabetes: Diabetes is a "risk equivalent" in most guidelines. Even without established ASCVD, diabetic patients benefit from statin therapy. Moderate-to-high intensity statin is typically recommended.

Chronic kidney disease: Statins benefit CKD patients not on dialysis. For dialysis patients, evidence is mixed (SHARP showed benefit, but 4D and AURORA did not in diabetic dialysis patients).